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Abstract
Severe anaemia has been one of the causes of high maternal mortality and the death of
newborns and infants due to low birth-weight in India. The prevalence of anaemia among
women of ages between 15 - 44 is extremely high, and ranges between 34 percent to 99
percent in rural India. Government of India has provide iron and folic acid tablets (IFA) as
a prophylaxis against nutritional anaemia among pregnant women as an integral part of
the Child Survival and Safe Motherhood program will continue to do so in the Reproductive
and Child Health package. The 1992-93 National Family Health Survey of India indicates
that only fifty percent of births were to mothers who had received IFA tablets, suggesting
the coverage and the intake was very inadequate. This paper presents findings of both
qualitative and quantitative research conducted among pregnant women to investigate the
extent of distribution and use, information provision and their knowledge and perceptions
regarding IFA tablets and reasons for non-use of IFA tablets. The study shows that the
consumption rate of the IFA tablets is high if women are knowledgeable and have positive
perceived experiences after taking the tablets. Findings suggest that more accurate and
complete information should be provided to pregnant women while distributing the IFA
tablets along with health and nutrition education messages. At the same time, follow-up
visits and counselling to the women are essential to address symptoms that are not related
to IFA.
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Introduction
Anaemia, a result of the adverse effects of iron deficiency, is one of the main causes of
maternal deaths in developing countries (WHO, 1989, and Mathai, 1987). Iron deficiency
may be due to inadequate diet or poor absortion of iron due to morbidity. While
prevalence rates in developed countries for iron deficiency anaemia range from 10 to 20
percent (Scrimshaw, 1984), two-thirds of women in developing countries are estimated
to be anaemic (WHO, 1989). In rural India, prevalence of anaemia among women of
ages between 15 - 44 ranges between 34 percent to 99 percent according to a study
conducted in Hyderabad, Calcutta, and New Delhi (GOI, 1981). The 1992-93 National
Family Health Survey of India indicates that only fifty percent of births were to mothers
who had received IFA tablets, suggesting the intake was very inadequate (IIPS, 1995).
This figure is even lower (30 percent) in Uttar Pradesh.
The prevalence rates of anaemia are even higher among pregnant women. The
estimated haemoglobin levels of pregnant women were less than 11 g/dl according to
studies conducted in various parts of India (Rao, 1980). In Bihar and Uttar Pradesh, the
mean haemoglobin levels among pregnant women were as low as 9.2 g/dl.d (Agarwal,
et al. 1987). During pregnancy, growth of the fetus and of the uterus, and other changes
taking place, lead to an increase in the demand for many nutrients, especially iron and
folic acid. Hence, pregnant women require iron to replace basal losses, to allow for the
expansion of the red cell mass, and to provide for the needs of the foetus and placenta.
In communities where parasitic infections are common, there is further loss of dietary
iron. In such circumstances, dietary iron take should be increased in proportion to the
degree of blood loss and anti helmentics are also prescribed.
At the onset of pregnancy, about 20 percent of women are anaemic and it increases to
over 60 percent by the last trimester. At the same time, up to 20 percent of pregnant
women are deficient in folic acid too. (Agarwal, 1984 and Raman, 1980).
Various studies (Scrimshaw, 1984; Viteri 1981; GOI, 1981) have indicated that iron
deficiency anaemia impairs resistance to infection, cognitive performance, physical
capacity, and work output which eventually is likely to effect economic development and
social welfare. Studies showed that workers became more willing, intelligent, and
effective workers reflecting overall increase in work capacity with iron supplementation
(Scrimshaw, 1984, GOI, 1981 and Rahamathullah, 1983). Additionally, severe anaemia
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with folate deficiency also increases the chances of delivering low birth-weight babies
(Mathai, 1987), an important underlying cause of death in newborns and infants in India.
Newborn babies with low birth-weight constitute about 30 percent of newborns in India
(GOI, 1991).
Government of India’s National Child Survival and Safe Motherhood (CSSM) Programme
(GOI, 1994) outlines that distribution of Iron Folic Acid (IFA) Tablets to pregnant women
is a part of essential care that should be provided to all pregnant women. IFA tablet
contains 60 mg of elemental iron and 0.5 mg of acid. Recently, it has been included as
a component of Reproductive and Child Health package of the National Family Welfare
Program. While pregnant women are having three antenatal checkups, health workers
distribute IFA tablets to all pregnant women (1 tablet a day for 100 days and to those
clinical anaemia 2 tablets a day for 100 days). The paleness seen in the nails, tongue,
inside of lower eyelids and complaints of weakness or dizziness are visible signs of
anaemia. Anaemia is also confirmed by checking haemoglobin level. Those found having
below 11 gms% are considered clinical anaemic and are recommended to take 2 tablets
daily for at least three months and continued till delivery (GOI, 1994). When the
haemoglobin level is below 7 gm% or less, woman is considered suffering from severe
anaemia. This article investigates the extent of distribution and use of IFA tablets,
information provision to pregnant women and their knowledge and perceptions regarding
IFA tablets.

Method
Data for this study was collected from three blocks (Achhnera, Akola, and Fatehpur Sikri)
of Agra district in Uttar Pradesh. These blocks have been chosen because an Operations
Research (OR) program to improve family welfare services is undergoing since April
1995. OR program includes activities which aim to improve access and quality of family
welfare services, including services to pregnant women.
A total of 153 pregnant women, randomly selected from the CSSM register maintained
by Auxiliary Nurse Midwives (ANMs) were contacted and interviewed. Within each block,
seven ANMs were randomly selected and from each ANM’s CSSM register, 10 pregnant
women registered during April 1995 to March 1996, were selected randomly. While
providing services to pregnant women, the ANM registers the names of pregnant women
who had received antenatal services including IFA tablets.
A two-page questionnaire was administered to all respondents. Each respondent was
asked whether they had received IFA tablets and information; if they were informed about
IFA tablets, and what information was provided. Following these questions, they were
asked whether they consumed the IFA tablets, their perceptions about IFA tablets,
whether it helped to improve their health and experience of side effects, if any. For those
who did not consume the IFA tablets or consumed only some of them, an attempt was
made to understand reasons for not taking the IFA tablets. Information was also
2
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supplemented by conducting qualitative interviews with an additional 63 pregnant women
who received antenatal services. Qualitative interviews were conducted at the client’s
home over a three-month period.
In the analysis, the sample of pregnant women are categorized into four groups
according to the current use status of the IFA. The categories are: 1) Used all- women
who consumed all IFA tablets given to them; 2) Used partially - women who consumed
only some the tablets given to them; 3) Not used at all - women who did not consume any
IFA tablets given to them; and 4) Still continuing - women who are still continuing to take
IFA tablets. Later in the analysis to study relationship with selected variables, they were
further categorized into three groups: used all, partial used, and not used.

Results
Characteristics
Table 1 presents the characteristics of pregnant women receiving IFA tablets. A little over
one-third (36 percent) of the respondents are under the age of 25 years, two-fifths (42
percent) within the age-group 25-29 years and one-fifth (22 percent) 30 years and above.
The mean age of sample pregnant women receiving IFA tablets was 26.5 years (Table
1). About one-third of the sample respondents were pregnant for the first and second
times, 45 percent were pregnant for the third and the fourth times. About one-fifth were
on the fifth pregnancy or even higher.
Table 1:

Characteristics of the pregnant women receiving IFA tablets (N=153)

Characteristics

Number of cases

Percentage

Age of respondent
Less than 25 years
25 - 29 years
30 or more
Mean age = 26.5 years

53
62
23

36
42
22

Pregnancy
1-2
3-4
5 or more
Mean pregnancies= 3.5

48
69
36

31
45
24

Note:

Total number of cases may not add up to 153 because of ‘not ascertained’ cases.

Table 2 provides information on the total number of IFA tablets distributed to pregnant
women. Recently, this has been remedied by providing sealed packets of 25 tablets.
While the majority of the women received less than 76 tablets, two-fifths were given 100
or more tablets. About five percent were provided with 25 tablets and very small
proportion (less than two percent) got 125 tablets or more (not shown in table). The
3
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normal practice as recommended by the GOI is to provide 100 tablets over three visits
(50 in the first visit and 25 in each second and third visit) during the antenatal period. In
contrast to what GOI has directed health workers to distribute IFA tablets for 100 days
(one per day), the workers’ registers indicate that they had been distributing between 25
and 175 tablets to each pregnant women. When the women were asked how many they
received, the study found discrepancies between the number of IFA tablets given as
recorded in the register and number actually received according to the women. As we
observed from our field visits, the pregnant women neither counted the number of the IFA
tablets given to them nor were they told how many were there in the packet by the female
health worker. Similarly, some women revealed during informal discussion that they
refused the IFA tablets because they did not like them. All these reasons would lead to
discrepancies between the two figures.
Table 2: Distribution of the pregnant women receiving IFA tablets according to
selected variables (N=153)
Characteristics

Number of cases

Percentage

Number of IFA tablets given to a woman
25 -50 tablets
51 -75 tablets
76 -99 tablets
100 tablets or more

61
25
67

40
16
44

Whether knew of effects of IFA tablets at time of
receiving
Yes
No

81
72

53
47

Current Use Status of IFA tablets
Used all
Used partially
Not used at all
Still continuing

62
45
22
24

41
29
14
16

121
32

79
21

Whether IFA tablets should be consumed
Yes
No
Note:

Total number of cases may not add up to 153 because of ‘not ascertained’ cases.
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Table 2 indicates that a little over one-half of the pregnant women knew about the effects
of IFA tablets on their bodies. The sample of pregnant women includes approximately
one-fifth (41 percent) who used or consumed all the tablets given to them, while less than
one third (29 percent) partially used the tablets and 14 percent did not use them at all.
About 16 percent of them still continue to take the IFA tablets told. Of the 153 sampled
pregnant women who received the IFA tablets, the majority of them were supposed to
have finished the given IFA tablets at the time of study, while one-fifth (21 percent) had
still time left to finish the supplied tablets.

Perceived Knowledge and Provision of Information
Among the women who claimed to know what IFA tablets are for, about three-fourths
perceived that it would provide strength to them. Sixteen percent thought that it
increased iron in the blood and 9 percent felt that it helped bowel movements. About 6 7 percent felt that either it helped to relieve their own sense of weakness or improve their
baby’s health. Few women thought that it helped to improve calcium deficiency, relieve
pain, provide more milk for the baby, and ease problems during delivery.
The knowledge of pregnant women about what IFA tablets do to women and children was
closely related to what the health workers told them. For example, among those who were
told that by taking the IFA tablets the women would gain strength, more than 80 percent
of them said that the benefit of taking the IFA tablets was to improve their strength.
The following messages should be provided to the pregnant women while distributing the
IFA tablets:
1.
2.
3.
4.
5.
6.

Must be taken daily for at least three months and continued till delivery.
Best if taken after meal.
Must take one tablet daily or 2 tablets daily if the woman is clinically anaemic.
After the use of tablets, colour of the stools is black but it is nothing to worry
about.
Some women may get nausea or constipation after starting IFA tablets but it lasts
only for a few days.
Must be continued as they are life saving.

The study findings indicate that the above information was not given to the women. Six
different pieces of information were provided to the pregnant women on the procedure
of how to take and when to take the IFA tablets. These messages were: take one tablet
daily, take after evening meal, take after morning meal, take after meal, take with milk,
and take with water.
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Few
women
received
complete information on how
to take and when to take
these tablets (three percent
in case of “take daily one
tablet after evening meal
with milk” and one percent in
case of “take daily one tablet
after evening meal with
water”).
Twenty-eight
percent of the women were
told “take one tablet daily” by
the health workers, while 45
percent were told “take after
evening meal”, 28 percent
“take after morning meal”, 42
percent “take with milk”, and only 14 percent “take with water”(Figure 1). Among the
pregnant women who were given information on its benefit, the majority of them (55
percent) were told that they would gain their strength by taking the IFA tablets. Less than
8 percent were informed that babies’ health could improve, increase in blood, improve
bowel movements, increase appetite, improve digestive power, improve calcium, gain in
weight, or relieve dizziness or pain. Importantly, however, none were informed of possible
side-effects after taking the tablets.
In general, health workers provided women with limited information on the procedure to
take IFA tablets and how it helps the woman’s health. Only 45 percent of the pregnant
women received two or more directions on the procedure to take the IFA tablets (Table
3).Those receiving two or more directives on the benefits of taking the IFA tablets were
only 12 percent. According to the sampled women, more than 50 percent got only one
piece of information or no information at all on the procedure. More than one-third (36
percent) did not receive any information on its benefits.
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Table 3: Percentage Distribution of Pregnant Women according to Number of
Pieces of Information given by Health Worker
Number

Percentage

Number of messages given by HW on how to take IFA
0
1
2
3+

32
51
38
32

21
33
25
21

Number of messages given by HW on benefits of IFA
0
1
2+

55
79
19

36
52
12

Perceived Experienced
More than 80 percent of the pregnant women who received the IFA tablets actually used
them. Information on experiences after taking the IFA tablets were only asked to those
who took the IFA tablets.
Figure 2 presents information
on the perceived experiences
after taking the IFA tablets.
About 21 percent of the
pregnant women reported that
they did not experience
dizziness after taking the IFA
tablets.
Eleven
percent
reported that their appetite
had improved and about 16
percent stated having regular
bowel movements. About 13
percent felt that the pain in
their hands and body had
disappeared. Contrary to what
the health workers had said to
the women, none reported
having gained strength by
taking the IFA tablets. Only 8 percent reported that it helped relieve some weakness.
Fifteen percent were found to have experienced improvement in their health status after
taking the IFA tablets.
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There was a small proportion of women who experienced side-effects after taking the IFA
tablets. To reiterate, no woman was informed of any possible side-effects by taking the
IFA tablets by the health workers. The perceived side-effects by women taking the
medicine were “vomiting” (2 percent) and “abdominal pain” (3 percent). Women also
reported their negative feelings regarding the colour of the stool, leading to
discontinuation of use. However, when asked about their perception of IFA tablets, more
than two-thirds of the women said that the IFA tablets were good for their health.
Current use status
Of these 153 sampled pregnant women who received the IFA tablets, the majority of them
were supposed to have finished the given IFA tablets by the time of the study. One-fifth
(21 percent) had still time left to finish the supplied tablets. The current use status of the
sampled women was based on 121 currently pregnant women who finished all the IFA
tablets supplied to them.The current use status has been divided into three categories:
used all, partial used, and not used. Of those who were due to finish the IFA tablets, a
little over two-fifths (44 percent) consumed all the tablets given to them, while about the
same proportion consumed only some, and about 14 percent did not use them at all. The
following results indicate the current IFA use status of women, whether use was affected
by severity of anaemia, knowledge about IFA, and type of information given.
Table 4: Current Use Status of the Pregnant Women who Received the IFA Tablets
by Selected Characteristics
Current Use Status
Characteristics

Number
cases

Used all

Partially used

Not used at all

Age
Less than 25 years
25-29 years
30 + years

36
52
39

49
39
42

15
10
19

39
52
26

Pregnancy
1
2+

39
46

49
40

12
15

33
88

Number of IFA supplied*
25 - 50 tablets
51 - 75 tablets
100 + tablets

24
45
57

56
55
28

20
15

41
20
60

of

Knew benefits about IFA*
62
37
2
63
Yes
24
48
28
58
No
Notes: * indicates significant at 1 percent level. ** indicates significant at 5 percent level. N.A= not
applicable. ‘-’ no case in the cell. Numbers refer to row percentages.

Table 4 shows that demographic variables, such as age of pregnant women and parity
did not have significant effect on the current use status. However, the first panel of Table
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5 suggests that those who were likely to have used all the supplied IFA tablets were
women 25-29 years of age (52 percent).
Table 5: Current Use Status of the Pregnant Women who Received the IFA Tablets
by Different Types of Advice Received and Perceived Experience
Current Use Status
Used all

Partially
used

Not used at all

Number
of
cases

55
43

41
43

4
13

49
60

Advised to take daily one tablet after
morning meal
Yes
No

52
48

48
39

13

31
77

Advised to take daily one tablet after
evening meal**
Yes
No

57
42

41
42

2
16

51
57

Advised to take daily one tablet
Yes
No

23
59

53
37

23
4

30
78

Advised to take because it provides
strength
Yes
No

55
43

41
43

4
13

49
60

Characteristics

Advised to take daily one tablet with
milk
Yes
No

Perceived experience of having some
positive change
57
43
N.A.
Yes
86
28
72
43
No
Notes: * indicates significant at 1 percent level. ** indicates significant at 5 percent level. N.A= not
applicable. ‘-’ no case in the cell. Numbers refer to row percentages.

Depending upon the severity of anaemia, health workers are advised to distribute IFA
tablets to all pregnant women (1 tablet a day for 100 days and to those with clinical
anaemia 2 tablets a day for 100 days). Those receiving more than 100 IFA tablets
constituted about 50 percent of users. Among this group of pregnant women, data
indicate that more than half (57 percent) consumed all the tablets supplied to them. The
percentage of those using all the tablets significantly decreased as the number of IFA
tablets provided decreased (45 percent in case of the group receiving 75 tablets and 24
percent in case of 25-50 tablets). Whether the pregnant woman used all the supplied IFA
tablets is also dependent upon her knowledge about the IFA tablets. Data indicate that
the percentage of pregnant women who used all the IFA tablets is two and half times
9
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more among those who knew about the benefits of the IFA tablets than those who did not
know. Also those not knowledgeable about the benefits are also highly likely not to use
at all as compared to those who knew.
Availability of information on howto take IFA tablets and when to take them has shown
to have a different relationship with current use status. If the pregnant women were told
to take one IFA tablet daily with milk, 55 percent of them were likely to have used all the
tablets, otherwise only 43 percent used all. Among those informed to take one tablet daily
after evening meal, 57 percent used all the tablets supplied, while only 42 did so among
those not informed. If the pregnant women were told to take “daily one tablet”, the
proportion of those using all the tablets is very low. In fact, there is a negative impact if
they were given this instruction.This implies that ambiguous information without clear
directions leads women to discontinue use.
Pregnant women who felt better after taking the IFA tablets also were more likely to finish
all the tablets supplied to them compared to those who did not perceive such a positive
effect. Fifty-seven percent of the pregnant women who used all the tablets felt better with
the IFA tablets, while only 28 percent of those who did not feel better took all the tablets.

Reasons for not using IFA tablets
Lack of knowledge regarding the importance of IFA supplementation has been one of the
most frequently given reasons for not taking the IFA tablets in the qualitative studies.
Provision of information by a health worker is an important activity as a woman’s husband
mentioned to the researcher. Some pointed out that they disliked the taste and hence,
they discontinued using the IFA tablets. The following provides some quotations from
respondents on reasons for not taking the IFA tablets by pregnant women.
“The remaining tablets I did not take because I did not know advantages
of the IFA tablets and therefore, I did not pay much attention to taking the
tablets.”
“My wife should be motivated by a female health worker to take the IFA
tablets regularly by telling the importance of the IFA tablets during the
entire pregnancy period.”
“I did not take a single tablet because I did not like the colour and taste”.
Table 6 shows the percentage of the pregnant women who did not use IFA at all or used
partially according to their reasons. There were 58 pregnant women in this category.
Almost one-third (31 percent) said that they did not know the reason(s) for not taking the
tablets. About 12 percent stopped taking them because it caused vomiting after taking
the IFA tablets. Some women did not have good feelings while taking them. These figures
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suggest that many of these reasons could be unrelated to the IFA tablets and could have
avoided by providing counselling, follow-up and information on a regular basis.
Table 6: Percentage of The Pregnant Women Who did not Use or Use Partially IFA
Supplied to Them by Reasons for not Using
Reason

Percentage

Pain
Uneasy feeling within abdomen
Did not feel good taking them
Bleeding
Vomiting
Dizziness
Afraid
No advantage
Constipation
Fever
Abdomen filled with gas
Don’t know
Forget to take regularly
No milk to take
Note: Percentages will not add up to 100 because of multiple responses.

3
5
17
2
12
9
2
5
3
10
3
31
10
3

When the pregnant women were asked whether they would recommend the IFA tablets
to others, four-fifths said they would recommend them. Their responses were largely
based on the perceived knowledge that the IFA tablets would provide strength to these
women.
At present, IFA is available only in packets containing 25 tablets. When asked one-fifth
expressed their intention to use the IFA, if the IFA was in an attractive packing or a
different form other than tablet, possibly in the syrup form. The majority said they would
not accept it if presented in a different form or package. Among those who expressed
their intention to use it, if presented in the different form or package, 22 out of 31 belong
to the category “used partially” or “not used ” indicating that the use rate might go up if
available in more than one form or package.
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Discussion
The study found that the health workers were distributing fewer IFA tablets than they are
supposed to as prescribed by the GOI (1 tablet a day for 100 days for all pregnant
women and 2 tablets a day for 100 days to those clinical anaemic). In addition, many
women reported receiving less quantity than the health workers actually reported in their
registers. This suggests that health workers need to improve their recording system as
well as adhere to the GOI’s rule by making a regular supervision.
With regards to the use status of the IFA tablets among women who should have
consumed all the IFA tablets, only 44 percent took all supplied to them. The consumption
rates of the IFA tablets were high among women aged between 25-29 years and those
receiving a large quantity of the IFA tablets (100 tablets or more). Whether a woman had
any knowledge about the IFA tablets at the time of receiving has much to do with the use
status. Those who knew about it are two times more likely to consume all the tablets
compared to those who did not know. Most pregnant women perceived that it helped to
build their strength.
A majority of the women were not even informed of the effects of IFA tablets, neither
benefit nor drawbacks. Information given by health workers on how and when to take the
tablets was fragmented, diverse, and inconsistent. Provision of accurate and complete
information to the women is important to increase the consumption rate of the IFA tablets.
We have found that a combination of information, such as “take after evening meal with
milk or “take after evening or morning meal ” improved the chances of taking all the
supplied tablets. Also the health workers should avoid giving incomplete information,
such as “take daily one tablet” because it will leave many other questions, such as when
and how to take it, unanswered. More importantly, an element of the quality care, such
asthe personal contact of friendly nature would improve taking of IFA tablets by women.
Perceived experience is another factor that determines the use status of the IFA tablets.
As we found from the above analysis that women who felt good or benefited from the IFA
tablets were more likely to consume all the tablets given to them. Women’s experiences
are important when they are not sure the medicine is doing good for their health. It is
essential that the health workers not only provide information at the beginning but also
make follow-up visits and provide more information while they are taking the IFA tablets,
contacting before they discontinue the medicine.
Integrated Child Development Services (ICDS), a multi-sectoral program of the
government of India covers a wide range of services including pregnant women. ICDS
clearly identifies the need for supplementary nutrition program for the rural pregnant
women and nursing mothers to decrease maternal morbidity and mortality. Certain health
education messages on supplementary nutrition, such as “...should eat more than she
eats normally...”, ...should eat plenty of green leafy vegetables” should be more widely
communicated through health network. Ž
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